SKB264 Innovative Cancer Antibody Drug Conjugate Clinical Trials Efficacy Insight [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Delhi, Sept. 19, 2024 (GLOBE NEWSWIRE) -- SKB264, also known as MK-2870, is an innovative antibody-drug conjugate (ADC) targeting TROP2, currently being developed by Kelun Biotech in partnership with MSD (Merck & Co., Inc.). Developed by OptiDC, Kelun Biotech's renowned international ADC R&D platform, SKB264 utilizes a proprietary payload-linker strategy called the Kthiol design. This strategy achieves an optimized balance of safety and efficacy by incorporating novel irreversible antibody conjugation chemistry, pH-sensitive payload release mechanisms, and site-specific moderately potent toxin molecules, boasting a drug-to-antibody ratio (DAR) of 7.4 with topoisomerase I inhibitors. Global Cancer Antibody Drug Conjugates Clinical Trials Insight Report Currently More Than 15 Cancer Antibody Drug Conjugates Available In Market More Than 600 Cancer Antibody Drug Conjugates In Clinical Trials Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck Loses Around $32B in 3 Months: Time to Sell the Stock? [Yahoo! Finance]Yahoo! Finance
- Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers [Yahoo! Finance]Yahoo! Finance
- Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic CancersBusiness Wire
- Merck's Keytruda Obtains its First FDA Approval for Mesothelioma [Yahoo! Finance]Yahoo! Finance
- Korean Biotech's Shares Quadruple In Seven Months, Becomes Kosdaq's Biggest Stock [Forbes]Forbes
MRK
Earnings
- 7/30/24 - Beat
MRK
Sec Filings
- 8/6/24 - Form 4
- 8/5/24 - Form 10-Q
- 7/30/24 - Form 8-K
- MRK's page on the SEC website